Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MYC | P01106 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9572754 | 0.87 | KCNH2 (0.59) | KMT2AMEN1KDM4ENR4A2ALDH1A1 | |
| SCHEMBL10258241 | 0.87 | KMT2A (0.52) | KMT2AMEN1KDM4ECDK2F7 | |
| SCHEMBL13114466 | 0.85 | KDM4E (0.64) | KMT2AMEN1KDM4ECDK2NR4A2 | |
| SCHEMBL4419843 | 0.84 | KMT2A (0.50) | KMT2AMEN1KDM4ECDK2NR4A2 | |
| SCHEMBL30622587 | 0.83 | KMT2A (0.56) | KMT2AMEN1KDM4ECDK2NR4A2 | |
| SCHEMBL12167181 | 0.83 | KMT2A (0.56) | KMT2AMEN1KDM4ECDK2NR4A2 | |
| SCHEMBL8356629 | 0.83 | NR4A2 (0.64) | KMT2AMEN1KDM4ENR4A2ALDH1A1 | |
| SCHEMBL13415460 | 0.83 | GFER (0.52) | KMT2AMEN1KDM4ENR4A2ALDH1A1 | |
| SCHEMBL13415459 | 0.83 | NR4A2 (0.64) | KMT2AKDM4ENR4A2KCNH2MAOB | |
| SCHEMBL14115041 | 0.83 | KMT2A (0.49) | KMT2AKDM4ECDK2NR4A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023277630-A1 | GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR | 주식회사 티움바이오 | 2023-01-05 | — | — | WO | disclosed |
| CN-104936950-B | The carboxamide derivative of 1H indoles 3 and its purposes as P2Y12 antagonists | 赛诺菲 | 2017-08-08 | — | — | CN | disclosed |
| US-9522140-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2016-12-20 | — | — | US | disclosed |
| US-9101616-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2015-08-11 | — | — | US | disclosed |
| US-9101616-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2015-08-11 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| EP-2061759-B1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8324251-B2 | Cyclic modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324251-B2 | Cyclic modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100093798-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| WO-2008095908-A1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008042926-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-10 | — | — | WO | disclosed |
| US-5877202-A | Indole derivatives useful to treat estrogen-related neoplasms and disorders | AVENTISUB II INC. | 1999-03-02 | — | — | US | disclosed |
| EP-0746544-B1 | NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS | MERRELL PHARMA INC (US) | 1998-09-09 | — | — | EP | disclosed |
| CN-1141627-A | Indole derivatives for the treatment of estrogen-related tumors and diseases | MERRELL DOW PHARMA (US) | 1997-01-29 | — | — | CN | disclosed |
| EP-0746544-A1 | NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS | MERRELL PHARMACEUTICALS INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995022524-A1 | NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS | MERRELL PHARMACEUTICALS INC. (US) | 1995-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093798-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CXCR1, CCR3 | KMT2A 4249/4885MEN1 3535/4885KDM4E 4223/4885 |
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | CCR9, IDO1, CCR10 | KMT2A 3255/4885MEN1 4615/4885KDM4E 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.